Keyphrases
APOBEC Signature
11%
Blood Tumor mutational Burden
100%
Burden Test
11%
Circulating Tumor DNA (ctDNA)
22%
Clinical Benefit
11%
Clinical Biomarkers
11%
Clinical Progression
11%
Copy number
55%
Cyclin-dependent Kinase 4 (CDK4)
100%
DNA Analysis
11%
Early Disease Progression
11%
Endocrine Therapy
22%
Estrogen Receptor 1 (ESR1)
11%
Fulvestrant
11%
Gene Panel
11%
Genetic Modification
11%
Genome Complexity
100%
Genomic Features
11%
HER2 Metastatic Breast Cancer
11%
HER2-negative Metastatic Breast Cancer
100%
HER2-positive
11%
High Correlation
11%
Letrozole
11%
Low-pass Sequencing
11%
Mutational Signatures
11%
Novel Treatments
11%
Palbociclib
11%
Phase II Trial
11%
Plasma Samples
11%
Poor Outcome
11%
Progression-free Survival
11%
Radiographic Progression
11%
Resistance to Endocrine Therapy
100%
Serial Monitoring
11%
Treatment Monitoring
11%
Treatment Resistance
11%
Whole Exome Sequencing
22%
Medicine and Dentistry
Apolipoprotein B mRNA Editing Enzyme Catalytic Polypeptide Like
11%
Biological Marker
11%
Circulating Tumor DNA
22%
Disease Exacerbation
11%
DNA Determination
11%
Exome Sequencing
22%
Fulvestrant
11%
Hormone Therapy
100%
Immunotherapy
11%
Letrozole
11%
Metastatic Breast Cancer
100%
Neoplasm
100%
Palbociclib
11%
Patient Monitoring
11%
Phase II Trials
11%
Progression Free Survival
11%
Whole Genome Sequencing
11%
Pharmacology, Toxicology and Pharmaceutical Science
Apolipoprotein B mRNA Editing Enzyme Catalytic Polypeptide Like
11%
Biological Marker
11%
Circulating Tumor DNA
22%
Disease Exacerbation
11%
Endocrine Therapy
100%
Fulvestrant
11%
Immunotherapy
11%
Letrozole
11%
Metastatic Breast Cancer
100%
Neoplasm
100%
Palbociclib
11%
Phase II Trials
11%
Progression Free Survival
11%
Biochemistry, Genetics and Molecular Biology
APOBEC
25%
Blood Plasma
25%
Circulating Tumor DNA
50%
DNA Analysis
25%
Exome Sequencing
50%
Fulvestrant
25%
Genomics
100%
Letrozole
25%
Phase II Trials
25%
Progression Free Survival
25%
Whole Genome Sequencing
25%